To evaluate the role of OPA3 in K-ras-driven cancer cells, we first used shRNA strategy to construct a stable OPA3-knockdown cell line from Panc-1 cells, a human pancreatic cell line harboring K-rasG12D mutation. The gene discussed is KRAS; the disease is cancer.